AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 06:00 ET
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
February 21, 2023 05:00 ET
|
Amydis, Inc.
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today...
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies
September 02, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
June 28, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
January 11, 2021 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
September 23, 2019 07:00 ET
|
Amydis, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases,...
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
October 24, 2018 07:00 ET
|
Amydis, Inc.
LOS ANGELES, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by...
IGC Announces Results of Annual Shareholders Meeting
November 13, 2017 14:22 ET
|
India Globalization Capital
BETHESDA, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), announced that during its 2016-2017 Annual Meeting of Shareholders scheduled for, and convened...
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
October 18, 2017 08:00 ET
|
India Globalization Capital
BETHESDA, Md., Oct. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vitro data compiled from genetically engineered cell lines within an...
IGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro Data
October 04, 2017 08:00 ET
|
India Globalization Capital
BETHESDA, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines...